Investing Warburg Pincus Style
Warburg Pincus' favored health care business models eliminate as much time and risk as possible from the drug discovery and development process. Competition for such investments is increasing, but Warburg reckons its size, and experience, set it apart.
You may also be interested in...
Current European-based specialty pharma companies are in transition, awaiting key regulatory decisions, overhauling management or engaged in M&A. Their fates will help answer a critical question: under what circumstances can this class of companies continue to deliver long term growth as independent entities?
About a year after Novo A/S announced the launch of its Growth Equity Fund, the firm has found a home for its first significant investment, contributing £40 million of a £65 million ($100 million) round for privately-owned UK-based specialty pharma firm Archimedes Pharma. Participants describe this as the largest private European biopharma fundraising in the last 15 years.
Archimedes joins a growing new generation of pan-European specialty pharma, highlighting the need for a single commercial partner across Europe and the increasing alternatives to big and mid-sized pharma.